Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 211 to 220 of 1106 total matches.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019 (Issue 1583)
-cell tumors (based on
animal data; no corroborating human data); the drug
is contraindicated ...
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.
Clascoterone Cream (Winlevi) for Acne
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
.
PREGNANCY AND LACTATION — There are no data on
the use of clascoterone 1% cream in pregnant women ...
The FDA has approved Winlevi (Sun), a 1% cream
formulation of the androgen receptor inhibitor
clascoterone, for treatment of acne vulgaris in
patients ≥12 years old. It is the first topical androgen
receptor inhibitor to be approved by the FDA.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020 (Issue 1600)
, and reverse
causation could have affected the results.9
Pregnancy and Lactation – Data on the use of topical ...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
In Brief: Clopidogrel and Omeprazole
The Medical Letter on Drugs and Therapeutics • Nov 29, 2010 (Issue 1352)
should also take a PPI, but not
omeprazole. Until more data become available on other
PPIs ...
Use of a proton pump inhibitor (PPI) to protect against gastrointestinal (GI) bleeding in patients taking the antiplatelet agent clopidogrel (Plavix) may interfere with the activation of clopidogrel and diminish its antiplatelet effect, increasing the risk of cardiovascular events.1 A randomized, placebo-controlled trial (COGENT) has found that use of the PPI omeprazole in patients taking clopidogrel in addition to aspirin decreased the incidence of GI bleeding without increasing the risk of a cardiovascular event, but the number of cardiovascular events was small and the formulation of...
Elderberry for Influenza
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
.
PREGNANCY AND LACTATION — No data are available
on the safety of elderberry use during pregnancy or
while ...
Patients may ask about taking elderberry for prevention
and treatment of influenza. Products containing
elderberry are promoted for relief of cold and flu
symptoms and as an immune system booster.
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
— No data are available to evaluate the
efficacy of glycopyrrolate as an adjunct to a proton
pump ...
The FDA has approved adjunctive treatment with
Dartisla ODT (Edenbridge), a new orally disintegrating
tablet (ODT) formulation of the anticholinergic drug
glycopyrrolate, to reduce symptoms of a peptic ulcer.
Glycopyrrolate oral tablets (Robinul, Robinul Forte,
and generics) were approved for the same indication
in 1961.
Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
▪ No data in patients with severe influenza
▪ Not recommended for use in severely immunocompromised ...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e1-5 doi:10.58347/tml.2024.1717d | Show Introduction Hide Introduction
In Brief: Label Changes for Testosterone Products
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
has required changes in the labels of all
testosterone products to reflect new data on their
cardiovascular ...
The FDA has required changes in the labels of all
testosterone products to reflect new data on their
cardiovascular effects. The updated labels will no
longer include a boxed warning about an increased risk
of adverse cardiovascular outcomes, but will contain a
new warning about an increase in blood pressure.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):62-3 doi:10.58347/tml.2025.1726d | Show Introduction Hide Introduction
Sunscreens
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
≥30.7 The FDA
has proposed a maximum labeled SPF value of 60+
because data showing that sunscreen ...
Excessive exposure to ultraviolet (UV) radiation can
cause erythema, photoaging, and skin cancer.
Sunscreens are widely used to reduce these risks, but
questions remain about their effectiveness and safety.
In 2021, the FDA proposed a rule that would require
additional safety studies for some sunscreen active
ingredients and mandate better UVA protection in
sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102 doi:10.58347/tml.2025.1731a | Show Introduction Hide Introduction
Zaleplon for Insomnia
The Medical Letter on Drugs and Therapeutics • Oct 08, 1999 (Issue 1063)
with the lowest recommended dose according to wholesale price (AWP) listings in First DataBank NDDF, August 20 ...
Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.